nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADK—Purine salvage—PNP—osteoporosis	0.0538	0.137	CbGpPWpGaD
Vidarabine—ADA—Purine salvage—PNP—osteoporosis	0.0365	0.0928	CbGpPWpGaD
Vidarabine—ADK—Purine metabolism—PNP—osteoporosis	0.0255	0.0648	CbGpPWpGaD
Vidarabine—ADK—Purine metabolism—ATIC—osteoporosis	0.0255	0.0648	CbGpPWpGaD
Vidarabine—ADA—Purine metabolism—ATIC—osteoporosis	0.0173	0.0441	CbGpPWpGaD
Vidarabine—ADA—Purine metabolism—PNP—osteoporosis	0.0173	0.0441	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—PNP—osteoporosis	0.0128	0.0326	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—ATIC—osteoporosis	0.0128	0.0326	CbGpPWpGaD
Vidarabine—Cladribine—PNP—osteoporosis	0.0104	0.763	CrCbGaD
Vidarabine—ADA—Nucleotide metabolism—ATIC—osteoporosis	0.00872	0.0221	CbGpPWpGaD
Vidarabine—ADA—Nucleotide metabolism—PNP—osteoporosis	0.00872	0.0221	CbGpPWpGaD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—LEP—osteoporosis	0.00788	0.02	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—ID4—osteoporosis	0.00778	0.0198	CbGpPWpGaD
Vidarabine—ADK—Purine metabolism—GPX1—osteoporosis	0.00723	0.0184	CbGpPWpGaD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—LEP—osteoporosis	0.007	0.0178	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—REN—osteoporosis	0.00613	0.0156	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—TNFRSF11B—osteoporosis	0.00545	0.0138	CbGpPWpGaD
Vidarabine—ADA—Purine metabolism—GPX1—osteoporosis	0.00492	0.0125	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—COL1A2—osteoporosis	0.00454	0.0115	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—ID4—osteoporosis	0.00447	0.0114	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—WNT1—osteoporosis	0.00412	0.0105	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—VDR—osteoporosis	0.00398	0.0101	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—ACE—osteoporosis	0.00382	0.00971	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—GPX1—osteoporosis	0.00363	0.00923	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—PTH1R—osteoporosis	0.0036	0.00915	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—CALCR—osteoporosis	0.0036	0.00915	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—VDR—osteoporosis	0.00356	0.00904	CbGpPWpGaD
Vidarabine—Glucosamine—TNF—osteoporosis	0.00324	0.237	CrCbGaD
Vidarabine—ADA—Nucleotide metabolism—GPX1—osteoporosis	0.00247	0.00627	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—LEP—osteoporosis	0.00238	0.00603	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—POMC—osteoporosis	0.00204	0.00518	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CCT2—osteoporosis	0.00201	0.00512	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—IGF1—osteoporosis	0.00196	0.00499	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—PTH—osteoporosis	0.00189	0.00481	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—TUBA1B—osteoporosis	0.00171	0.00435	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—IL1B—osteoporosis	0.00158	0.00402	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—PTHLH—osteoporosis	0.00157	0.00398	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—CALCA—osteoporosis	0.00138	0.00351	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—RPL24—osteoporosis	0.00137	0.00348	CbGpPWpGaD
Vidarabine—ADK—Metabolism—FDPS—osteoporosis	0.00134	0.00341	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PKM—osteoporosis	0.00134	0.00341	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Raloxifene—osteoporosis	0.00134	0.00226	CcSEcCtD
Vidarabine—Hyperhidrosis—Ibandronate—osteoporosis	0.00133	0.00224	CcSEcCtD
Vidarabine—Hypoaesthesia—Conjugated Estrogens—osteoporosis	0.00133	0.00224	CcSEcCtD
Vidarabine—Nausea—Ergocalciferol—osteoporosis	0.00132	0.00223	CcSEcCtD
Vidarabine—Urticaria—Etidronic acid—osteoporosis	0.00132	0.00222	CcSEcCtD
Vidarabine—Bronchospasm—Estradiol—osteoporosis	0.00131	0.00221	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—PTH1R—osteoporosis	0.00131	0.00332	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CALCR—osteoporosis	0.00131	0.00332	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Estropipate—osteoporosis	0.00131	0.0022	CcSEcCtD
Vidarabine—Angioedema—Ethinyl Estradiol—osteoporosis	0.0013	0.00219	CcSEcCtD
Vidarabine—Tension—Pamidronate—osteoporosis	0.00129	0.00218	CcSEcCtD
Vidarabine—Dysgeusia—Pamidronate—osteoporosis	0.00129	0.00218	CcSEcCtD
Vidarabine—Paraesthesia—Estropipate—osteoporosis	0.00129	0.00217	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Alendronate—osteoporosis	0.00129	0.00217	CcSEcCtD
Vidarabine—Cardiac disorder—Zoledronate—osteoporosis	0.00128	0.00217	CcSEcCtD
Vidarabine—Flushing—Zoledronate—osteoporosis	0.00128	0.00217	CcSEcCtD
Vidarabine—Nervousness—Pamidronate—osteoporosis	0.00128	0.00216	CcSEcCtD
Vidarabine—Abdominal discomfort—Estradiol—osteoporosis	0.00128	0.00216	CcSEcCtD
Vidarabine—Back pain—Pamidronate—osteoporosis	0.00128	0.00215	CcSEcCtD
Vidarabine—Somnolence—Estropipate—osteoporosis	0.00127	0.00215	CcSEcCtD
Vidarabine—ADK—Metabolism—GPD2—osteoporosis	0.00127	0.00323	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PGLS—osteoporosis	0.00127	0.00323	CbGpPWpGaD
Vidarabine—Angioedema—Risedronate—osteoporosis	0.00127	0.00214	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Raloxifene—osteoporosis	0.00126	0.00213	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Ibandronate—osteoporosis	0.00125	0.00211	CcSEcCtD
Vidarabine—Mediastinal disorder—Zoledronate—osteoporosis	0.00125	0.0021	CcSEcCtD
Vidarabine—Syncope—Risedronate—osteoporosis	0.00124	0.0021	CcSEcCtD
Vidarabine—Cough—Ethinyl Estradiol—osteoporosis	0.00124	0.0021	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAP1A—osteoporosis	0.00124	0.00315	CbGpPWpGaD
Vidarabine—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.00124	0.00209	CcSEcCtD
Vidarabine—Arrhythmia—Zoledronate—osteoporosis	0.00124	0.00209	CcSEcCtD
Vidarabine—Paraesthesia—Ibandronate—osteoporosis	0.00123	0.00208	CcSEcCtD
Vidarabine—Pollakiuria—Estradiol—osteoporosis	0.00123	0.00208	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.00123	0.00207	CcSEcCtD
Vidarabine—Pain—Estropipate—osteoporosis	0.00123	0.00207	CcSEcCtD
Vidarabine—Hypersensitivity—Etidronic acid—osteoporosis	0.00122	0.00206	CcSEcCtD
Vidarabine—Loss of consciousness—Risedronate—osteoporosis	0.00122	0.00206	CcSEcCtD
Vidarabine—Agitation—Pamidronate—osteoporosis	0.00121	0.00205	CcSEcCtD
Vidarabine—Cough—Risedronate—osteoporosis	0.00121	0.00204	CcSEcCtD
Vidarabine—Anxiety—Ethinyl Estradiol—osteoporosis	0.00121	0.00204	CcSEcCtD
Vidarabine—Pain—Alendronate—osteoporosis	0.00121	0.00204	CcSEcCtD
Vidarabine—Angioedema—Pamidronate—osteoporosis	0.00121	0.00203	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—TLN1—osteoporosis	0.0012	0.00306	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.0012	0.00203	CcSEcCtD
Vidarabine—Hypertension—Risedronate—osteoporosis	0.0012	0.00202	CcSEcCtD
Vidarabine—Discomfort—Ethinyl Estradiol—osteoporosis	0.0012	0.00202	CcSEcCtD
Vidarabine—Somnolence—Calcitriol—osteoporosis	0.0012	0.00202	CcSEcCtD
Vidarabine—Arrhythmia—Conjugated Estrogens—osteoporosis	0.00119	0.00201	CcSEcCtD
Vidarabine—Pain—Raloxifene—osteoporosis	0.00119	0.002	CcSEcCtD
Vidarabine—Syncope—Pamidronate—osteoporosis	0.00118	0.002	CcSEcCtD
Vidarabine—Chest pain—Risedronate—osteoporosis	0.00118	0.00199	CcSEcCtD
Vidarabine—Dysgeusia—Zoledronate—osteoporosis	0.00118	0.00199	CcSEcCtD
Vidarabine—Anxiety—Risedronate—osteoporosis	0.00118	0.00199	CcSEcCtD
Vidarabine—Pain—Ibandronate—osteoporosis	0.00118	0.00198	CcSEcCtD
Vidarabine—Acute coronary syndrome—Estradiol—osteoporosis	0.00117	0.00198	CcSEcCtD
Vidarabine—Back pain—Zoledronate—osteoporosis	0.00117	0.00197	CcSEcCtD
Vidarabine—ADK—Metabolism—PNP—osteoporosis	0.00116	0.00296	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ATIC—osteoporosis	0.00116	0.00296	CbGpPWpGaD
Vidarabine—Myocardial infarction—Estradiol—osteoporosis	0.00116	0.00197	CcSEcCtD
Vidarabine—Loss of consciousness—Pamidronate—osteoporosis	0.00116	0.00196	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—REN—osteoporosis	0.00116	0.00294	CbGpPWpGaD
Vidarabine—Dry mouth—Risedronate—osteoporosis	0.00116	0.00195	CcSEcCtD
Vidarabine—Cough—Pamidronate—osteoporosis	0.00115	0.00194	CcSEcCtD
Vidarabine—Pain—Calcitriol—osteoporosis	0.00115	0.00194	CcSEcCtD
Vidarabine—ADORA2A—Monoamine Transport—TNF—osteoporosis	0.00115	0.00292	CbGpPWpGaD
Vidarabine—Convulsion—Pamidronate—osteoporosis	0.00114	0.00193	CcSEcCtD
Vidarabine—Hypertension—Pamidronate—osteoporosis	0.00114	0.00192	CcSEcCtD
Vidarabine—Tension—Conjugated Estrogens—osteoporosis	0.00114	0.00192	CcSEcCtD
Vidarabine—Urticaria—Estropipate—osteoporosis	0.00114	0.00192	CcSEcCtD
Vidarabine—Dysgeusia—Conjugated Estrogens—osteoporosis	0.00114	0.00192	CcSEcCtD
Vidarabine—Vision blurred—Zoledronate—osteoporosis	0.00114	0.00192	CcSEcCtD
Vidarabine—Tremor—Zoledronate—osteoporosis	0.00113	0.0019	CcSEcCtD
Vidarabine—Nervousness—Conjugated Estrogens—osteoporosis	0.00113	0.0019	CcSEcCtD
Vidarabine—Back pain—Conjugated Estrogens—osteoporosis	0.00112	0.00189	CcSEcCtD
Vidarabine—Urticaria—Alendronate—osteoporosis	0.00112	0.00189	CcSEcCtD
Vidarabine—Anxiety—Pamidronate—osteoporosis	0.00112	0.00189	CcSEcCtD
Vidarabine—Shock—Risedronate—osteoporosis	0.00111	0.00188	CcSEcCtD
Vidarabine—Discomfort—Pamidronate—osteoporosis	0.00111	0.00187	CcSEcCtD
Vidarabine—Agitation—Zoledronate—osteoporosis	0.00111	0.00187	CcSEcCtD
Vidarabine—Angioedema—Zoledronate—osteoporosis	0.0011	0.00186	CcSEcCtD
Vidarabine—Vision blurred—Conjugated Estrogens—osteoporosis	0.00109	0.00185	CcSEcCtD
Vidarabine—Urticaria—Ibandronate—osteoporosis	0.00109	0.00184	CcSEcCtD
Vidarabine—Syncope—Zoledronate—osteoporosis	0.00108	0.00182	CcSEcCtD
Vidarabine—Anaphylactic shock—Pamidronate—osteoporosis	0.00108	0.00182	CcSEcCtD
Vidarabine—Urticaria—Calcitriol—osteoporosis	0.00107	0.0018	CcSEcCtD
Vidarabine—Palpitations—Zoledronate—osteoporosis	0.00106	0.0018	CcSEcCtD
Vidarabine—Hypoaesthesia—Estradiol—osteoporosis	0.00106	0.00179	CcSEcCtD
Vidarabine—Angioedema—Conjugated Estrogens—osteoporosis	0.00106	0.00179	CcSEcCtD
Vidarabine—Shock—Pamidronate—osteoporosis	0.00106	0.00179	CcSEcCtD
Vidarabine—Loss of consciousness—Zoledronate—osteoporosis	0.00106	0.00179	CcSEcCtD
Vidarabine—Hypersensitivity—Estropipate—osteoporosis	0.00106	0.00178	CcSEcCtD
Vidarabine—Vomiting—Etidronic acid—osteoporosis	0.00105	0.00178	CcSEcCtD
Vidarabine—Cough—Zoledronate—osteoporosis	0.00105	0.00177	CcSEcCtD
Vidarabine—Tachycardia—Pamidronate—osteoporosis	0.00105	0.00177	CcSEcCtD
Vidarabine—Rash—Etidronic acid—osteoporosis	0.00104	0.00176	CcSEcCtD
Vidarabine—Convulsion—Zoledronate—osteoporosis	0.00104	0.00176	CcSEcCtD
Vidarabine—Dermatitis—Etidronic acid—osteoporosis	0.00104	0.00176	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—MYC—osteoporosis	0.00104	0.00265	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Pamidronate—osteoporosis	0.00104	0.00176	CcSEcCtD
Vidarabine—Syncope—Conjugated Estrogens—osteoporosis	0.00104	0.00176	CcSEcCtD
Vidarabine—Hypertension—Zoledronate—osteoporosis	0.00104	0.00176	CcSEcCtD
Vidarabine—Hypersensitivity—Alendronate—osteoporosis	0.00104	0.00175	CcSEcCtD
Vidarabine—Headache—Etidronic acid—osteoporosis	0.00104	0.00175	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Risedronate—osteoporosis	0.00103	0.00174	CcSEcCtD
Vidarabine—Asthenia—Estropipate—osteoporosis	0.00103	0.00173	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.00103	0.00261	CbGpPWpGaD
Vidarabine—Chest pain—Zoledronate—osteoporosis	0.00103	0.00173	CcSEcCtD
Vidarabine—Palpitations—Conjugated Estrogens—osteoporosis	0.00103	0.00173	CcSEcCtD
Vidarabine—Anxiety—Zoledronate—osteoporosis	0.00102	0.00172	CcSEcCtD
Vidarabine—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.00102	0.00172	CcSEcCtD
Vidarabine—Paraesthesia—Risedronate—osteoporosis	0.00102	0.00172	CcSEcCtD
Vidarabine—Discomfort—Zoledronate—osteoporosis	0.00101	0.00171	CcSEcCtD
Vidarabine—Asthenia—Alendronate—osteoporosis	0.00101	0.00171	CcSEcCtD
Vidarabine—Hypersensitivity—Ibandronate—osteoporosis	0.00101	0.00171	CcSEcCtD
Vidarabine—Cough—Conjugated Estrogens—osteoporosis	0.00101	0.00171	CcSEcCtD
Vidarabine—Dyspnoea—Risedronate—osteoporosis	0.00101	0.0017	CcSEcCtD
Vidarabine—Hypotension—Pamidronate—osteoporosis	0.00101	0.0017	CcSEcCtD
Vidarabine—Convulsion—Conjugated Estrogens—osteoporosis	0.00101	0.0017	CcSEcCtD
Vidarabine—Dry mouth—Zoledronate—osteoporosis	0.001	0.00169	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—LEP—osteoporosis	0.000995	0.00253	CbGpPWpGaD
Vidarabine—Tinnitus—Estradiol—osteoporosis	0.000995	0.00168	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—MYC—osteoporosis	0.000993	0.00252	CbGpPWpGaD
Vidarabine—Hypersensitivity—Calcitriol—osteoporosis	0.000991	0.00167	CcSEcCtD
Vidarabine—ADK—Metabolism—CA2—osteoporosis	0.000991	0.00252	CbGpPWpGaD
Vidarabine—ADK—Metabolism—OXCT1—osteoporosis	0.000991	0.00252	CbGpPWpGaD
Vidarabine—Cardiac disorder—Estradiol—osteoporosis	0.00099	0.00167	CcSEcCtD
Vidarabine—Flushing—Estradiol—osteoporosis	0.00099	0.00167	CcSEcCtD
Vidarabine—Chest pain—Conjugated Estrogens—osteoporosis	0.000988	0.00167	CcSEcCtD
Vidarabine—Asthenia—Ibandronate—osteoporosis	0.000986	0.00166	CcSEcCtD
Vidarabine—Anxiety—Conjugated Estrogens—osteoporosis	0.000984	0.00166	CcSEcCtD
Vidarabine—Nausea—Etidronic acid—osteoporosis	0.000984	0.00166	CcSEcCtD
Vidarabine—Anaphylactic shock—Zoledronate—osteoporosis	0.000983	0.00166	CcSEcCtD
Vidarabine—ADORA2A—G alpha (s) signalling events—ADCY5—osteoporosis	0.000982	0.0025	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000981	0.00166	CcSEcCtD
Vidarabine—Pain—Risedronate—osteoporosis	0.000968	0.00163	CcSEcCtD
Vidarabine—Shock—Zoledronate—osteoporosis	0.000967	0.00163	CcSEcCtD
Vidarabine—Paraesthesia—Pamidronate—osteoporosis	0.000967	0.00163	CcSEcCtD
Vidarabine—ADK—Metabolism—MGLL—osteoporosis	0.000965	0.00245	CbGpPWpGaD
Vidarabine—Asthenia—Calcitriol—osteoporosis	0.000965	0.00163	CcSEcCtD
Vidarabine—Mediastinal disorder—Estradiol—osteoporosis	0.000961	0.00162	CcSEcCtD
Vidarabine—Dyspnoea—Pamidronate—osteoporosis	0.00096	0.00162	CcSEcCtD
Vidarabine—Tachycardia—Zoledronate—osteoporosis	0.00096	0.00162	CcSEcCtD
Vidarabine—Somnolence—Pamidronate—osteoporosis	0.000957	0.00161	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—RAP1A—osteoporosis	0.000953	0.00242	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Zoledronate—osteoporosis	0.000951	0.0016	CcSEcCtD
Vidarabine—Dizziness—Estropipate—osteoporosis	0.000948	0.0016	CcSEcCtD
Vidarabine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000947	0.0016	CcSEcCtD
Vidarabine—Dizziness—Alendronate—osteoporosis	0.000933	0.00157	CcSEcCtD
Vidarabine—Shock—Conjugated Estrogens—osteoporosis	0.000932	0.00157	CcSEcCtD
Vidarabine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000924	0.00156	CcSEcCtD
Vidarabine—Urticaria—Ethinyl Estradiol—osteoporosis	0.000923	0.00156	CcSEcCtD
Vidarabine—Pain—Pamidronate—osteoporosis	0.000921	0.00155	CcSEcCtD
Vidarabine—Hypotension—Zoledronate—osteoporosis	0.000919	0.00155	CcSEcCtD
Vidarabine—Dizziness—Raloxifene—osteoporosis	0.000918	0.00155	CcSEcCtD
Vidarabine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000915	0.00154	CcSEcCtD
Vidarabine—ADA—Metabolism—FDPS—osteoporosis	0.000913	0.00232	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PKM—osteoporosis	0.000913	0.00232	CbGpPWpGaD
Vidarabine—Tension—Estradiol—osteoporosis	0.000911	0.00154	CcSEcCtD
Vidarabine—Vomiting—Estropipate—osteoporosis	0.000911	0.00154	CcSEcCtD
Vidarabine—Dysgeusia—Estradiol—osteoporosis	0.000909	0.00153	CcSEcCtD
Vidarabine—Dizziness—Ibandronate—osteoporosis	0.000909	0.00153	CcSEcCtD
Vidarabine—Rash—Estropipate—osteoporosis	0.000904	0.00152	CcSEcCtD
Vidarabine—Dermatitis—Estropipate—osteoporosis	0.000903	0.00152	CcSEcCtD
Vidarabine—Nervousness—Estradiol—osteoporosis	0.000902	0.00152	CcSEcCtD
Vidarabine—Urticaria—Risedronate—osteoporosis	0.0009	0.00152	CcSEcCtD
Vidarabine—Back pain—Estradiol—osteoporosis	0.000898	0.00152	CcSEcCtD
Vidarabine—Headache—Estropipate—osteoporosis	0.000898	0.00151	CcSEcCtD
Vidarabine—Vomiting—Alendronate—osteoporosis	0.000897	0.00151	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000896	0.00151	CcSEcCtD
Vidarabine—Rash—Alendronate—osteoporosis	0.00089	0.0015	CcSEcCtD
Vidarabine—Dermatitis—Alendronate—osteoporosis	0.000889	0.0015	CcSEcCtD
Vidarabine—Hypotension—Conjugated Estrogens—osteoporosis	0.000885	0.00149	CcSEcCtD
Vidarabine—Headache—Alendronate—osteoporosis	0.000884	0.00149	CcSEcCtD
Vidarabine—Paraesthesia—Zoledronate—osteoporosis	0.000883	0.00149	CcSEcCtD
Vidarabine—Vomiting—Raloxifene—osteoporosis	0.000883	0.00149	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.00088	0.00223	CbGpPWpGaD
Vidarabine—Dyspnoea—Zoledronate—osteoporosis	0.000877	0.00148	CcSEcCtD
Vidarabine—Rash—Raloxifene—osteoporosis	0.000875	0.00148	CcSEcCtD
Vidarabine—Dermatitis—Raloxifene—osteoporosis	0.000874	0.00148	CcSEcCtD
Vidarabine—Somnolence—Zoledronate—osteoporosis	0.000874	0.00148	CcSEcCtD
Vidarabine—Vomiting—Ibandronate—osteoporosis	0.000874	0.00147	CcSEcCtD
Vidarabine—Tremor—Estradiol—osteoporosis	0.00087	0.00147	CcSEcCtD
Vidarabine—Headache—Raloxifene—osteoporosis	0.00087	0.00147	CcSEcCtD
Vidarabine—Rash—Ibandronate—osteoporosis	0.000866	0.00146	CcSEcCtD
Vidarabine—ADA—Metabolism—PGLS—osteoporosis	0.000866	0.0022	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GPD2—osteoporosis	0.000866	0.0022	CbGpPWpGaD
Vidarabine—Dermatitis—Ibandronate—osteoporosis	0.000866	0.00146	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000863	0.00146	CcSEcCtD
Vidarabine—Headache—Ibandronate—osteoporosis	0.000861	0.00145	CcSEcCtD
Vidarabine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000856	0.00144	CcSEcCtD
Vidarabine—Vomiting—Calcitriol—osteoporosis	0.000855	0.00144	CcSEcCtD
Vidarabine—Agitation—Estradiol—osteoporosis	0.000853	0.00144	CcSEcCtD
Vidarabine—Nausea—Estropipate—osteoporosis	0.000851	0.00144	CcSEcCtD
Vidarabine—Paraesthesia—Conjugated Estrogens—osteoporosis	0.00085	0.00143	CcSEcCtD
Vidarabine—Angioedema—Estradiol—osteoporosis	0.000848	0.00143	CcSEcCtD
Vidarabine—Rash—Calcitriol—osteoporosis	0.000848	0.00143	CcSEcCtD
Vidarabine—Dermatitis—Calcitriol—osteoporosis	0.000847	0.00143	CcSEcCtD
Vidarabine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000844	0.00142	CcSEcCtD
Vidarabine—Headache—Calcitriol—osteoporosis	0.000843	0.00142	CcSEcCtD
Vidarabine—Somnolence—Conjugated Estrogens—osteoporosis	0.000842	0.00142	CcSEcCtD
Vidarabine—Pain—Zoledronate—osteoporosis	0.000841	0.00142	CcSEcCtD
Vidarabine—Nausea—Alendronate—osteoporosis	0.000838	0.00141	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KL—osteoporosis	0.000836	0.00212	CbGpPWpGaD
Vidarabine—Hypersensitivity—Risedronate—osteoporosis	0.000834	0.00141	CcSEcCtD
Vidarabine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000833	0.00141	CcSEcCtD
Vidarabine—Syncope—Estradiol—osteoporosis	0.000833	0.00141	CcSEcCtD
Vidarabine—Nausea—Raloxifene—osteoporosis	0.000825	0.00139	CcSEcCtD
Vidarabine—ADK—Metabolism—IDH2—osteoporosis	0.000821	0.00208	CbGpPWpGaD
Vidarabine—Palpitations—Estradiol—osteoporosis	0.000821	0.00138	CcSEcCtD
Vidarabine—Nausea—Ibandronate—osteoporosis	0.000816	0.00138	CcSEcCtD
Vidarabine—Loss of consciousness—Estradiol—osteoporosis	0.000816	0.00138	CcSEcCtD
Vidarabine—Asthenia—Risedronate—osteoporosis	0.000813	0.00137	CcSEcCtD
Vidarabine—Cough—Estradiol—osteoporosis	0.00081	0.00137	CcSEcCtD
Vidarabine—Pain—Conjugated Estrogens—osteoporosis	0.00081	0.00137	CcSEcCtD
Vidarabine—Hypertension—Estradiol—osteoporosis	0.000802	0.00135	CcSEcCtD
Vidarabine—Nausea—Calcitriol—osteoporosis	0.000799	0.00135	CcSEcCtD
Vidarabine—Hypersensitivity—Pamidronate—osteoporosis	0.000793	0.00134	CcSEcCtD
Vidarabine—ADA—Metabolism—ATIC—osteoporosis	0.000792	0.00201	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PNP—osteoporosis	0.000792	0.00201	CbGpPWpGaD
Vidarabine—Chest pain—Estradiol—osteoporosis	0.000791	0.00133	CcSEcCtD
Vidarabine—Anxiety—Estradiol—osteoporosis	0.000788	0.00133	CcSEcCtD
Vidarabine—Urticaria—Zoledronate—osteoporosis	0.000781	0.00132	CcSEcCtD
Vidarabine—Discomfort—Estradiol—osteoporosis	0.000781	0.00132	CcSEcCtD
Vidarabine—Dry mouth—Estradiol—osteoporosis	0.000773	0.0013	CcSEcCtD
Vidarabine—Asthenia—Pamidronate—osteoporosis	0.000772	0.0013	CcSEcCtD
Vidarabine—ADK—Metabolism—CYP27A1—osteoporosis	0.000772	0.00196	CbGpPWpGaD
Vidarabine—Dizziness—Ethinyl Estradiol—osteoporosis	0.000768	0.0013	CcSEcCtD
Vidarabine—Anaphylactic shock—Estradiol—osteoporosis	0.000758	0.00128	CcSEcCtD
Vidarabine—Urticaria—Conjugated Estrogens—osteoporosis	0.000752	0.00127	CcSEcCtD
Vidarabine—ADK—Metabolism—ACP5—osteoporosis	0.000751	0.00191	CbGpPWpGaD
Vidarabine—Dizziness—Risedronate—osteoporosis	0.000749	0.00126	CcSEcCtD
Vidarabine—Shock—Estradiol—osteoporosis	0.000746	0.00126	CcSEcCtD
Vidarabine—Tachycardia—Estradiol—osteoporosis	0.00074	0.00125	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—CALCR—osteoporosis	0.000739	0.00188	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PTH1R—osteoporosis	0.000739	0.00188	CbGpPWpGaD
Vidarabine—Vomiting—Ethinyl Estradiol—osteoporosis	0.000739	0.00125	CcSEcCtD
Vidarabine—Hyperhidrosis—Estradiol—osteoporosis	0.000733	0.00124	CcSEcCtD
Vidarabine—Rash—Ethinyl Estradiol—osteoporosis	0.000732	0.00124	CcSEcCtD
Vidarabine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000732	0.00123	CcSEcCtD
Vidarabine—Headache—Ethinyl Estradiol—osteoporosis	0.000728	0.00123	CcSEcCtD
Vidarabine—Hypersensitivity—Zoledronate—osteoporosis	0.000725	0.00122	CcSEcCtD
Vidarabine—ADORA2A—G alpha (s) signalling events—POMC—osteoporosis	0.000723	0.00184	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—ACE—osteoporosis	0.000722	0.00183	CbGpPWpGaD
Vidarabine—Vomiting—Risedronate—osteoporosis	0.00072	0.00122	CcSEcCtD
Vidarabine—Rash—Risedronate—osteoporosis	0.000714	0.0012	CcSEcCtD
Vidarabine—Dermatitis—Risedronate—osteoporosis	0.000713	0.0012	CcSEcCtD
Vidarabine—Dizziness—Pamidronate—osteoporosis	0.000712	0.0012	CcSEcCtD
Vidarabine—Headache—Risedronate—osteoporosis	0.000709	0.0012	CcSEcCtD
Vidarabine—Asthenia—Zoledronate—osteoporosis	0.000706	0.00119	CcSEcCtD
Vidarabine—ADK—Metabolism—TPI1—osteoporosis	0.000698	0.00177	CbGpPWpGaD
Vidarabine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000698	0.00118	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Estradiol—osteoporosis	0.00069	0.00117	CcSEcCtD
Vidarabine—Nausea—Ethinyl Estradiol—osteoporosis	0.00069	0.00116	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—PTH—osteoporosis	0.000687	0.00175	CbGpPWpGaD
Vidarabine—Vomiting—Pamidronate—osteoporosis	0.000684	0.00116	CcSEcCtD
Vidarabine—Paraesthesia—Estradiol—osteoporosis	0.00068	0.00115	CcSEcCtD
Vidarabine—Asthenia—Conjugated Estrogens—osteoporosis	0.000679	0.00115	CcSEcCtD
Vidarabine—Rash—Pamidronate—osteoporosis	0.000679	0.00115	CcSEcCtD
Vidarabine—Dermatitis—Pamidronate—osteoporosis	0.000678	0.00114	CcSEcCtD
Vidarabine—Dyspnoea—Estradiol—osteoporosis	0.000676	0.00114	CcSEcCtD
Vidarabine—Headache—Pamidronate—osteoporosis	0.000674	0.00114	CcSEcCtD
Vidarabine—Somnolence—Estradiol—osteoporosis	0.000674	0.00114	CcSEcCtD
Vidarabine—ADA—Metabolism—OXCT1—osteoporosis	0.000673	0.00171	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CA2—osteoporosis	0.000673	0.00171	CbGpPWpGaD
Vidarabine—Nausea—Risedronate—osteoporosis	0.000673	0.00114	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—CALCR—osteoporosis	0.000671	0.00171	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTH1R—osteoporosis	0.000671	0.00171	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CNR2—osteoporosis	0.00067	0.0017	CbGpPWpGaD
Vidarabine—ADK—Metabolism—P4HB—osteoporosis	0.000656	0.00167	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MGLL—osteoporosis	0.000656	0.00167	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ADCY5—osteoporosis	0.000655	0.00166	CbGpPWpGaD
Vidarabine—Dizziness—Zoledronate—osteoporosis	0.00065	0.0011	CcSEcCtD
Vidarabine—Pain—Estradiol—osteoporosis	0.000648	0.00109	CcSEcCtD
Vidarabine—ADK—Metabolism—GAPDH—osteoporosis	0.000644	0.00164	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KL—osteoporosis	0.000643	0.00163	CbGpPWpGaD
Vidarabine—Nausea—Pamidronate—osteoporosis	0.000639	0.00108	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—WNT1—osteoporosis	0.00063	0.0016	CbGpPWpGaD
Vidarabine—ADK—Metabolism—RAP1A—osteoporosis	0.000627	0.00159	CbGpPWpGaD
Vidarabine—Dizziness—Conjugated Estrogens—osteoporosis	0.000626	0.00106	CcSEcCtD
Vidarabine—Vomiting—Zoledronate—osteoporosis	0.000625	0.00106	CcSEcCtD
Vidarabine—Rash—Zoledronate—osteoporosis	0.00062	0.00105	CcSEcCtD
Vidarabine—Dermatitis—Zoledronate—osteoporosis	0.000619	0.00105	CcSEcCtD
Vidarabine—Headache—Zoledronate—osteoporosis	0.000616	0.00104	CcSEcCtD
Vidarabine—Vomiting—Conjugated Estrogens—osteoporosis	0.000602	0.00102	CcSEcCtD
Vidarabine—Urticaria—Estradiol—osteoporosis	0.000602	0.00102	CcSEcCtD
Vidarabine—Rash—Conjugated Estrogens—osteoporosis	0.000597	0.00101	CcSEcCtD
Vidarabine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000596	0.00101	CcSEcCtD
Vidarabine—Headache—Conjugated Estrogens—osteoporosis	0.000593	0.001	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—MGLL—osteoporosis	0.000587	0.00149	CbGpPWpGaD
Vidarabine—Nausea—Zoledronate—osteoporosis	0.000584	0.000986	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS2—osteoporosis	0.000573	0.00145	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—LEP—osteoporosis	0.000572	0.00145	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—PTHLH—osteoporosis	0.00057	0.00145	CbGpPWpGaD
Vidarabine—Nausea—Conjugated Estrogens—osteoporosis	0.000562	0.000949	CcSEcCtD
Vidarabine—Hypersensitivity—Estradiol—osteoporosis	0.000558	0.000942	CcSEcCtD
Vidarabine—ADA—Metabolism—IDH2—osteoporosis	0.000558	0.00142	CbGpPWpGaD
Vidarabine—Asthenia—Estradiol—osteoporosis	0.000544	0.000917	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—MGLL—osteoporosis	0.000533	0.00135	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP27A1—osteoporosis	0.000525	0.00133	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ACP5—osteoporosis	0.00051	0.0013	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ENO1—osteoporosis	0.000507	0.00129	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ADCY5—osteoporosis	0.000503	0.00128	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CALCA—osteoporosis	0.000501	0.00127	CbGpPWpGaD
Vidarabine—Dizziness—Estradiol—osteoporosis	0.000501	0.000846	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IRS1—osteoporosis	0.0005	0.00127	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PSMA5—osteoporosis	0.0005	0.00127	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PSMA2—osteoporosis	0.0005	0.00127	CbGpPWpGaD
Vidarabine—Vomiting—Estradiol—osteoporosis	0.000482	0.000813	CcSEcCtD
Vidarabine—Rash—Estradiol—osteoporosis	0.000478	0.000806	CcSEcCtD
Vidarabine—Dermatitis—Estradiol—osteoporosis	0.000477	0.000806	CcSEcCtD
Vidarabine—Headache—Estradiol—osteoporosis	0.000475	0.000801	CcSEcCtD
Vidarabine—ADA—Metabolism—TPI1—osteoporosis	0.000474	0.0012	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6R—osteoporosis	0.00047	0.00119	CbGpPWpGaD
Vidarabine—Nausea—Estradiol—osteoporosis	0.00045	0.00076	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—LEP—osteoporosis	0.000449	0.00114	CbGpPWpGaD
Vidarabine—ADA—Metabolism—P4HB—osteoporosis	0.000446	0.00113	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IRS2—osteoporosis	0.00044	0.00112	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SOST—osteoporosis	0.000439	0.00111	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GAPDH—osteoporosis	0.000438	0.00111	CbGpPWpGaD
Vidarabine—ADA—Metabolism—RAP1A—osteoporosis	0.000426	0.00108	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP19A1—osteoporosis	0.000405	0.00103	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CALCR—osteoporosis	0.000397	0.00101	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTH1R—osteoporosis	0.000397	0.00101	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PTH—osteoporosis	0.000388	0.000987	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—POMC—osteoporosis	0.000385	0.000979	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IRS1—osteoporosis	0.000385	0.000977	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CNR2—osteoporosis	0.000379	0.000961	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—IL6—osteoporosis	0.000371	0.000943	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—IGF1—osteoporosis	0.000371	0.000941	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6R—osteoporosis	0.000361	0.000917	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTH—osteoporosis	0.000353	0.000896	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ENO1—osteoporosis	0.000345	0.000875	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000344	0.000875	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CNR2—osteoporosis	0.000344	0.000873	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PSMA5—osteoporosis	0.00034	0.000863	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PSMA2—osteoporosis	0.00034	0.000863	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ADCY5—osteoporosis	0.000331	0.000841	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GPX1—osteoporosis	0.00033	0.000838	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—WNT1—osteoporosis	0.000323	0.000821	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PTHLH—osteoporosis	0.000322	0.000817	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MGLL—osteoporosis	0.000315	0.0008	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LRP5—osteoporosis	0.000308	0.000781	CbGpPWpGaD
Vidarabine—ADK—Metabolism—MTHFR—osteoporosis	0.000305	0.000774	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LRP6—osteoporosis	0.000294	0.000747	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTHLH—osteoporosis	0.000292	0.000742	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CALCA—osteoporosis	0.000283	0.00072	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP19A1—osteoporosis	0.000276	0.0007	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—POMC—osteoporosis	0.000262	0.000666	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CALCA—osteoporosis	0.000257	0.000654	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TLN1—osteoporosis	0.000248	0.000631	CbGpPWpGaD
Vidarabine—ADK—Metabolism—POMC—osteoporosis	0.000244	0.000619	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ADCY5—osteoporosis	0.000225	0.000572	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GPX1—osteoporosis	0.000224	0.00057	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—P4HB—osteoporosis	0.000214	0.000544	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—osteoporosis	0.000213	0.000542	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—osteoporosis	0.000209	0.000531	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTH—osteoporosis	0.000208	0.000529	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MTHFR—osteoporosis	0.000207	0.000526	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RAP1A—osteoporosis	0.000205	0.00052	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CNR2—osteoporosis	0.000203	0.000516	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ADCY5—osteoporosis	0.000202	0.000512	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NFATC1—osteoporosis	0.0002	0.000507	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—DKK1—osteoporosis	0.000198	0.000503	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—WNT1—osteoporosis	0.000191	0.000485	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGA—osteoporosis	0.000186	0.000472	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADCY5—osteoporosis	0.000183	0.000465	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTHLH—osteoporosis	0.000173	0.000439	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BMP2—osteoporosis	0.000173	0.000439	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGB—osteoporosis	0.000169	0.000429	CbGpPWpGaD
Vidarabine—ADA—Metabolism—POMC—osteoporosis	0.000166	0.000421	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PSMA2—osteoporosis	0.000163	0.000414	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PSMA5—osteoporosis	0.000163	0.000414	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—osteoporosis	0.000161	0.000409	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CALCA—osteoporosis	0.000152	0.000386	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—POMC—osteoporosis	0.000148	0.000377	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KL—osteoporosis	0.000138	0.000351	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—POMC—osteoporosis	0.000135	0.000342	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6R—osteoporosis	0.000131	0.000334	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADCY5—osteoporosis	0.000108	0.000275	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SPP1—osteoporosis	0.000105	0.000266	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IRS2—osteoporosis	9.46e-05	0.00024	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LEP—osteoporosis	9.26e-05	0.000235	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ESR1—osteoporosis	8.84e-05	0.000224	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IRS1—osteoporosis	8.26e-05	0.00021	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—POMC—osteoporosis	7.95e-05	0.000202	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6R—osteoporosis	7.76e-05	0.000197	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1—osteoporosis	7.65e-05	0.000194	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—osteoporosis	5.85e-05	0.000149	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—osteoporosis	4.6e-05	0.000117	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFB1—osteoporosis	4.59e-05	0.000116	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—osteoporosis	3.46e-05	8.78e-05	CbGpPWpGaD
